Browsing by author "James, Nicholas"
Now showing items 41-60 of 73
-
Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021.
Gillessen, S; Armstrong, A; Attard, G; Beer, TM; Beltran, H; et al. (ELSEVIER, 2022-07-01)BACKGROUND: Innovations in treatments, imaging, and molecular characterisation in advanced prostate cancer have improved outcomes, but various areas of management still lack high-level evidence to inform clinical practice. ... -
Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019.
Gillessen, S; Attard, G; Beer, TM; Beltran, H; Bjartell, A; et al. (ELSEVIER, 2020-04-01)BACKGROUND: Innovations in treatments, imaging, and molecular characterisation in advanced prostate cancer have improved outcomes, but there are still many aspects of management that lack high-level evidence to inform ... -
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.
Gillessen, S; Attard, G; Beer, TM; Beltran, H; Bossi, A; et al. (ELSEVIER SCIENCE BV, 2018-02-01)BACKGROUND: In advanced prostate cancer (APC), successful drug development as well as advances in imaging and molecular characterisation have resulted in multiple areas where there is lack of evidence or low level of ... -
Mobile Health Solutions for Prostate Cancer Diagnostics-A Systematic Review.
Moghul, M; Cazzaniga, W; Croft, F; Kinsella, N; Cahill, D; et al. (MDPI, 2023-07-28)Prostate cancer, the most common cause of cancer in men in the UK and one of the most common around the world to date, has no consensus on screening. Multiple large-scale trials from around the world have produced conflicting ... -
MRE11 as a Predictive Biomarker of Outcome After Radiation Therapy in Bladder Cancer.
Walker, AK; Karaszi, K; Valentine, H; Strauss, VY; Choudhury, A; et al. (ELSEVIER SCIENCE INC, 2019-07-15)PURPOSE: Organ-confined muscle-invasive bladder cancer is treated with cystectomy or bladder preservation techniques, including radiation therapy. There are currently no biomarkers to inform management decisions and aid ... -
New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors.
Bamias, A; Merseburger, A; Loriot, Y; James, N; Choy, E; et al. (BMJ PUBLISHING GROUP, 2023-01-01)BACKGROUND: Bellmunt Risk Score, based on Eastern Cooperative Oncology Group (ECOG) performance status (PS), hemoglobin levels and presence of liver metastases, is the most established prognostic algorithm for patients ... -
Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by (Chemo)radiotherapy in the BC2001 Trial.
Hussain, SA; Porta, N; Hall, E; Salawu, A; Lewis, R; et al. (ELSEVIER, 2021-02-01)BACKGROUND: BC2001 demonstrated improved local control with the addition of chemotherapy to radiotherapy in 360 patients with muscle-invasive bladder cancer. OBJECTIVE: To establish whether such benefit remained in BC2001 ... -
Overall Survival in Men With Bone Metastases From Castration-Resistant Prostate Cancer Treated With Bone-Targeting Radioisotopes: A Meta-analysis of Individual Patient Data From Randomized Clinical Trials.
Terrisse, S; Karamouza, E; Parker, CC; Sartor, AO; James, ND; et al. (AMER MEDICAL ASSOC, 2020-02-01)IMPORTANCE: Both α-emitting and β-emitting bone-targeted radioisotopes (RIs) have been developed to treat men with metastatic castration-resistant prostate cancer (CRPC). Only 1 phase 3 randomized clinical trial has ... -
Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy ± Chemotherapy in the BC2001 Phase III Randomised Controlled Trial.
Huddart, RA; Hall, E; Lewis, R; Porta, N; Crundwell, M; et al. (ELSEVIER, 2020-02-01)BACKGROUND: BC2001, the largest randomised trial of bladder-sparing treatment for muscle-invasive bladder cancer, demonstrated improvement of local control and bladder cancer-specific survival from the addition of concomitant ... -
Patients choose certainty over burden in bladder cancer surveillance.
van Osch, FHM; Nekeman, D; Aaronson, NK; Billingham, LJ; James, ND; et al. (SPRINGER, 2019-12-01)BACKGROUND: Due to the high risk of recurrence of non-muscle invasive bladder cancer, all patients undergo regular cystoscopic surveillance for early detection. As cystoscopy is invasive, costly and increases the burden ... -
Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials units.
Love, SB; Cafferty, F; Snowdon, C; Carty, K; Savage, J; et al. (BMC, 2022-09-06)BACKGROUND: Late-phase platform protocols (including basket, umbrella, multi-arm multi-stage (MAMS), and master protocols) are generally agreed to be more efficient than traditional two-arm clinical trial designs but are ... -
Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from 'castration-resistant' prostate cancer.
Pezaro, CJ; Omlin, A; Mastris, K; ANZUP Consumer Advisory Panel,; Attard, G; et al. (OXFORD UNIV PRESS, 2017-08-01) -
Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract.
Sternberg, CN; Loriot, Y; James, N; Choy, E; Castellano, D; et al. (ELSEVIER SCIENCE BV, 2019-07-01)BACKGROUND: Atezolizumab, a humanised monoclonal antibody targeting PD-L1, is approved for locally advanced/metastatic urothelial carcinoma. SAUL evaluated atezolizumab in a broader, pretreated population, including patients ... -
Properties of non-coding mutation hotspots as urinary biomarkers for bladder cancer detection.
Baxter, L; Gordon, NS; Ott, S; Wang, J; Patel, P; et al. (NATURE PORTFOLIO, 2023-01-19)Mutations at specific hotspots in non-coding regions of ADGRG6, PLEKHS1, WDR74, TBC1D12 and LEPROTL1 frequently occur in bladder cancer (BC). These mutations could function as biomarkers for the non-invasive detection of ... -
Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis.
Burdett, S; Boevé, LM; Ingleby, FC; Fisher, DJ; Rydzewska, LH; et al. (ELSEVIER, 2019-07-01)BACKGROUND: Many trials are evaluating therapies for men with metastatic hormone-sensitive prostate cancer (mHSPC). OBJECTIVE: To systematically review trials of prostate radiotherapy. DESIGN, SETTING, AND PARTICIPANTS: ... -
Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial.
Rush, HL; Murphy, L; Morgans, AK; Clarke, NW; Cook, AD; et al. (LIPPINCOTT WILLIAMS & WILKINS, 2022-03-10)PURPOSE: Docetaxel and abiraterone acetate plus prednisone or prednisolone (AAP) both improve survival when commenced alongside standard of care (SOC) androgen deprivation therapy in locally advanced or metastatic ... -
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.
Parker, CC; James, ND; Brawley, CD; Clarke, NW; Hoyle, AP; et al. (ELSEVIER SCIENCE INC, 2018-12-01)BACKGROUND: Based on previous findings, we hypothesised that radiotherapy to the prostate would improve overall survival in men with metastatic prostate cancer, and that the benefit would be greatest in patients with a low ... -
Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial.
Parker, CC; James, ND; Brawley, CD; Clarke, NW; Ali, A; et al. (PUBLIC LIBRARY SCIENCE, 2022-06-01)BACKGROUND: STAMPEDE has previously reported that radiotherapy (RT) to the prostate improved overall survival (OS) for patients with newly diagnosed prostate cancer with low metastatic burden, but not those with high-burden ... -
Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer.
Sternberg, C; Armstrong, A; Pili, R; Ng, S; Huddart, R; et al. (AMER SOC CLINICAL ONCOLOGY, 2016-08-01)PURPOSE: Tasquinimod, a novel oral therapy targeting the tumor microenvironment, significantly improved progression-free survival (PFS) in a randomized, placebo-controlled phase II trial in men with metastatic castration-resistant ... -
Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era'': Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019)
James, ND; Spears, MR; Clarke, NW; Dearnaley, DP; De Bono, JS; et al. (Elsevier BV, 2015-06-01)